Accès ouvert déclaré
2021
article
Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure
Santiago Jiménez de Ory, Carolina Beltrán-Pavez, Miguel Gutiérrez-López, María del Mar Polo de Santos, Luis Prieto, Talía Sainz, Sara Guillén, David Aguilera‐Alonso, Cristina Díez, José Ignacio Bernardino, María José Mellado, José Tomás Ramos, África Holguín, Marisa Navarro, Luis Escosa, Milagros García López Hortelano, Pablo Rojo, Cristina Epalza, María Luisa Navarro, Jesús Saavedra, Begoña Santiago, Itzíar Carrasco, Arantxa Berzosa, David Aguilera, María Ángeles Muñoz‐Fernández, Miguel Ángel Roa, María Penín, Jorge Martínez, Katie Badillo, Ana Belén Jiménez, Adriana Navas, Eider Oñate, Itziar Pocheville, Elisa Garrote, Elena Colino, Jorge Gómez Sirvent, M. González-Ripoll Garzón, Vicente Román, Raquel Angulo, Olaf Neth, Lola Falcón-Neyra, Pedro Terol, Juan Luis Santos, Álvaro Vázquez, Francisco Lendínez, Estrella Peromingo, Beatriz Ruiz, Ana Grande, Francisco J. Romero, Carlos Pérez, Miguel Lillo, Begoña Losada, Mercedes Herranz, Matilde Bustillo Alonso, Miguel Lafuente, Pilar Collado, José Antonio Couceiro, Leticia Vila, Consuelo Calviño, Ana Isabel Piqueras, Manuel Oltra, César Gavilán, Elena Montesinos, Marta Dapena, Cristina Álvarez, Beatriz Jiménez, Ana Gloria Andrés, Víctor Marugán, Carlos Ochoa, Ana Isabel Menasalvas, Eloísa Cervantes, Pere Soler‐Palacín, Maria Antoinette Frick, Antonio Mǔr, Lluís Mayol, Teresa Vallmanya, Olga Calavia, Lourdes García, María Teresa Balaguer Coll, Valentí Pineda, Neus Rius, Joaquín Dueñas, Clàudia Fortuny, Antoni Noguera-Julian Ignacio Bernardino, Marisa Montes, Eulalia Valencia, Rafael Rubio, Federico Pulido, Otilia Bisbal, Gabriel Gaspar Alonso, Juan Berenguer, Teresa Aldámiz, Pedro Montilla, Elena Bermúdez, Maricela Valerio, José Sanz, Sari Arponen, Alejandra Gimeno, Miguel Cervero, Rafael Torres, Santiago Moreno, Ma Jesús Pérez, Pablo Ryan, Jesús Troya, Jesús Sanz, Juan Emilio Losa, Rafael Gómez, Miguel Górgolas, José Antonio Iribarren, Francisco Rodríguez, Lydia Pascual, María José Aramburu, Ane Josune Goikoetxea, Josefa Muñoz, Sofía Ibarra, Michele Hernández, Juan Luis Gómez Sirvent, Jehovana Rodríguez, Miguel Ángel Cárdenes, Luís F. López‐Cortés, Silvia Llaves, María Rios, Jesús Rodríguez, Virginia Palomo, Juan Pasquau, Coral García, José L. Hernández, Clara Martínez, Antonio Rivero, Ángela Camacho, Dolores Merino, Laura Corpa, Elisa Martínez, Fernando Mateos, José Javier Blanch, Miguel Torralba, Piedad Arazo, Gloria Sampériz, Celia Miralles, Antonio Ocampo, Guille Pousada, Álvaro Mena, Marta Montero, Miguel Salavert, Iván Castro Hernández, Sandra Cuéllar, Marı́a José Galindo, R Ferrando, Joaquín Portilla, Irene Portilla, Félix Gutiérrez, Mar Masiá, Cati Robledano, Araceli Adsuar, Carmen Hinojosa, Jésica Abadía, Carlos Galera, Helena Albendín, Marian Fernández, José Ramón Blanco, Joaquín Burgos, Berta Torres, Elisa de Lazzari
1Citations signalées, ce qui n’est pas une note de qualité
5Institutions déclarées
1Pays d’affiliation déclarés
Rattachement africain : es.
Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVES: We analysed the prevalence of M184V/I and/or K65R/E/N mutations archived in proviral DNA (pDNA) in youths with perinatal HIV, virological control and who previously carried these resistance mutations in historic plasma samples. METHODS: We included vertically HIV-infected youths/young adults aged ≥10 years in the Madrid Cohort of HIV-1 Infected Children and Adolescents, exposed to lamivudine and/or emtricitabine, with M184V/I and/or K65R/E/N in historic plasma samples, on antiretroviral therapy (ART), virologically suppressed (HIV-1 RNA <50 copies/mL), and with available PBMCs in the Spanish HIV BioBank. Genomic DNA was extracted from PBMCs and HIV-1 RT gene was amplified and sequenced for resistance testing by Stanford HIV Resistance tool. RESULTS: Among the 225 patients under follow-up in the study cohort, 13 (5.8%) met selection criteria, and RT sequences were recovered in 12 (92.3%) of them. All but one were Spaniards, carrying subtype B, with a median age at PBMCs sampling of 21.3 years (IQR: 15.6-23.1) with 4 years (IQR 2.1-6.5) of suppressed viral load (VL). Nine (75%) youths did not present M184V/I in pDNA after at least 1 year of viral suppression. In December 2019, the remaining three subjects carrying M184V/I in pDNA maintained suppressed viraemia, and two still used emtricitabine in ART. CONCLUSIONS: The prevalence of resistance mutations to lamivudine and emtricitabine in pDNA in a cohort of youths perinatally infected with HIV who remain with undetectable VL, previously lamivudine and/or emtricitabine experienced, was infrequent. Our results indicate that ART including lamivudine or emtricitabine may also be safe and successful in youths with perinatal HIV with previous experience of and resistances to these drugs detected in plasma.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure
- Date Crossref
- 18/03/2021
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Les institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.
Les sujets associés
HIV/AIDS drug development and treatmentViral-associated cancers and disordersHIV-related health complications and treatments